Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature MedicineGlobeNewsWire • 11/13/23
Kymera Therapeutics Merits Cautious 'Wait-And-See' Approach For Inflammatory Skin DiseasesSeeking Alpha • 11/12/23
Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual MeetingGlobeNewsWire • 11/02/23
Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business UpdateGlobeNewsWire • 11/02/23
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from SanofiGlobeNewsWire • 10/27/23
Will Kymera Therapeutics, Inc. (KYMR) Report Negative Q3 Earnings? What You Should KnowZacks Investment Research • 10/26/23
Kymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2GlobeNewsWire • 10/26/23
Kymera Therapeutics, Inc. (KYMR) Loses -33.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 10/19/23
Kymera Therapeutics, Inc. (KYMR) Loses -35.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 10/18/23
Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell CarcinomaGlobeNewsWire • 10/16/23
Kymera Therapeutics, Inc. (KYMR) Soars 14.3%: Is Further Upside Left in the Stock?Zacks Investment Research • 10/04/23
Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell LymphomaGlobeNewsWire • 09/18/23
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/03/23
Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business UpdateGlobeNewsWire • 08/03/23
Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3GlobeNewsWire • 07/27/23
Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid LeukemiaGlobeNewsWire • 06/22/23
Kymera Therapeutics' STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical TrialsGlobeNewsWire • 06/14/23
Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413GlobeNewsWire • 06/09/23
Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, Compared to Small Molecule Inhibitor in Preclinical Leukemia Models at the European Hematology Association CongressGlobeNewsWire • 06/09/23